Health care funds pull in sound returns despite pandemic

Our of the ten health care funds marketed in Finland, Pictet’s Biotech PUSD fund has performed best during the pandemic, writes Kauppalehti.


Only three of ten health care funds available in Finland have pulled in a negative return during the ongoing Coronavirus pandemic, reports Kauppalehti today.

The most successful fund, according to data from Morningstar and based on return since January 2020, is Pictet’s Biotech PUSD fund. The fund’s largest investments are in companies developing new drugs, such as Vertex Pharmaceuticcs and Gilead Sciences, whose drug is expected to help treating Covid-19. The fund's year to day return today stands at 10.6 percent.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

New paper slams model portfolio boom for conflict of interest

So-called model portfolios -- off-the-shelf investment strategies often comprising bundles of ETFs -- are ridden with conflicts of interest, according a trio of academics, including Associate Professor from the Norwegian School of Economics Nataliya Gerasimova.

Further reading

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch